SCHEMBL4698398

SCHEMBL4698398

CCOC(=O)c1c(N)c2cc(-c3ccc(C(C)(C)C)cc3)ccc2n1-c1ccc(OC(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGES O14684 3/20 0.55
PPARG P37231 7/20 0.40
PPARA Q07869 3/20 0.40
NR1H4 Q96RI1 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
THRB P10828 1/20 0.39
MAPT P10636 4/20 0.39
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 2/20 0.37
SERPINE1 P05121 1/20 0.37
POLB P06746 1/20 0.37
ADORA1 P30542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021254 0.90 PTGES (0.59) PTGESPPARGPPARANR1H4SMN1; SMN2
SCHEMBL334136 0.88 PTGES (0.53) PTGESPPARGPPARANR1H4SMN1; SMN2
SCHEMBL4700726 0.88 PTGES (0.53) PTGESPPARGPPARANR1H4SMN1; SMN2
SCHEMBL4698609 0.86 PTGES (0.51) PTGESPPARGPPARANR1H4SMN1; SMN2
SCHEMBL3012072 0.86 PTGES (0.51) PTGESPPARGPPARANR1H4SMN1; SMN2
SCHEMBL4700108 0.86 PTGES (0.51) PTGESPPARGPPARANR1H4SMN1; SMN2
SCHEMBL4698605 0.85 PTGES (0.50) PTGESPPARGPPARANR1H4SMN1; SMN2
SCHEMBL1407310 0.83 PTGES (0.49) PTGESPPARGPPARANR1H4SMN1; SMN2
SCHEMBL3000522 0.83 PTGES (0.48) PTGESSMN1; SMN2MAPTMEN1NPC1
SCHEMBL334000 0.83 PTGES (0.48) PTGESPPARGPPARANR1H4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778633-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2008-12-03 EP disclosed
US-20080188473-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188473-A1 Indoles Useful in the Treatment of Inflammation IDO1, PTGS1, PTGER1 PTGES 4/4885PPARG 753/4885PPARA 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.